Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrotic disease with high mortality. Currently, pirfenidone and nintedanib are the only approved drugs for IPF by the U.S. Food and Drug Administration (FDA), but their efficacy is limited. The activation of multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Meng, Liu, An-Dong, Niu, Qian, Feng, Xiao, Zheng, Yuan-Yi, Chen, Shuai-Jun, Xu, Hui, Li, Qian, Hou, Guo-Qing, Bi, Xiao-Yang, Lu, Yu-Zhi, Cheng, Pei-Pei, Liang, Li-Mei, Jiang, Ye-Han, Zhao, Li-Qin, Liu, Fei, Song, Lin-Jie, Zhou, Li-Ling, Xiao, Ling-Yan, Chen, Feng, Li, Shawn Shun-Cheng, Ma, Wan-Li, Cao, Xuan, Ye, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254236/
https://www.ncbi.nlm.nih.gov/pubmed/35832075
http://dx.doi.org/10.7150/thno.72269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254236/
https://www.ncbi.nlm.nih.gov/pubmed/35832075
http://dx.doi.org/10.7150/thno.72269

Ejemplares similares